Noriyuki Katsumata

Noriyuki Katsumata

Auto-generated profile, based on publicly available information

Noriyuki Katsumata

Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in The Lancet Oncology
Verified
Journal Article
Closed access
NKNoriyuki Katsumata
Noriyuki Katsumata
MYMakoto Yasuda
Makoto Yasuda
SISeiji Isonishi
Seiji Isonishi
FTFumiaki Takahashi
Fumiaki Takahashi
HMHirofumi Michimae
Hirofumi Michimae
KOKazunori Ochiai
Kazunori Ochiai

2 May 2013 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
OGon behalf of the Japan Clinical Oncology Group
on behalf of the Japan Clinical Oncology Group
NKN Katsumata
N Katsumata
HYH Yoshikawa
H Yoshikawa
HKH Kobayashi
H Kobayashi
TST Saito
T Saito
TKT Kamura
T Kamura
A phase III trial was conducted to determine whether neoadjuvant chemotherapy (NACT) before radical surgery (RS) improves overall survival. Patients with stage IB2, IIA2, or IIB squamous cell carcinoma of the uterine cervix were randomly assigned to receive either BOMP (bleomycin 7 mg days 1–5, vincristine 0.7 mg m−2 day 5, mitomycin 7 mg m−2 day 5, cisplatin 14 mg m−2 days 1–5, every 3 weeks for 2 to 4 cycles) plus RS (NACT group) or RS alone (RS group). Patients with pathological high-risk factors received postoperative radiotherapy (RT). The primary end point was overall survival. A total of 134 patients were randomly assigned to treatment. This study was prematurely terminated at the first planned interim analysis because overall survival in the NACT group was inferior to that in the RS group. Patients who received postoperative RT were significantly lower in the NACT group (58%) than in the RS group (80%; P=0.015). The 5-year overall survival was 70.0% in the NACT group and 74.4% in the RS group (P=0.85). Neoadjuvant chemotherapy with BOMP regimen before RS did not improve overall survival, but reduced the number of patients who received postoperative RT.

1 January 2014 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
KHK. Harano
K. Harano
FTF. Terauchi
F. Terauchi
NKN. Katsumata
N. Katsumata
FTF. Takahashi
F. Takahashi
MYM. Yasuda
M. Yasuda
TST. Sugiyama
T. Sugiyama
Dose-dense weekly paclitaxel (Taxol) and carboplatin (dd-TC) improved survival compared with conventional tri-weekly paclitaxel and carboplatin (c-TC) as a first-line chemotherapy for newly diagnosed stage II–IV ovarian cancer in the Japanese Gynecologic Oncology Group 3016 trial. We report the quality-of-life (QoL) results from this trial. A total of 637 patients were randomly assigned to receive c-TC or dd-TC (c-TC, n = 319; dd-TC, n = 312) and were asked to complete a QoL assessment at baseline, just after the third and sixth chemotherapy cycles, and at 12 months after randomization. QoL was assessed using Functional Assessment of Cancer Therapy (FACT)-general (FACT-G), FACT-taxane subscale (FACT-T), and FACT-ovary subscale (FACT-Ov). The overall QoL and that according to each subscale were analyzed using mixed-effects models adjusted for treatment and time. Baseline QoL assessment was completed by 204 out of 319 (63.9%) and 200 out of 312 (64.1%) patients in the c-TC and dd-TC groups, respectively. In these groups, the compliance rates with regard to QoL assessment were 74.5% and 73.0%, respectively, after three chemotherapy cycles; 86.8% and 86.9%, respectively, after six chemotherapy cycles; and 74.2% and 71.6%, respectively, at 12 months after randomization. The overall QoL did not differ significantly between the two treatment groups up to 12 months after randomization (P = 0.46). However, QoL according to the FACT-T subscale was significantly lower in the dd-TC group than in the c-TC group (P = 0.02). dd-TC does not decrease overall QoL compared with c-TC. NCT00226915.

1 October 2008 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
Shin NishioShin Nishio
Shin Nishio
NKNoriyuki Katsumata
Noriyuki Katsumata
KMKoji Matsumoto
Koji Matsumoto
HTHiroshi Tanabe
Hiroshi Tanabe
KYKan Yonemori
Kan Yonemori
YFYasuhiro Fujiwara
Yasuhiro Fujiwara

26 October 2010 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
MTMaki Tanioka
Maki Tanioka
NKNoriyuki Katsumata
Noriyuki Katsumata
KYKan Yonemori
Kan Yonemori
TKTsutomu Kouno
Tsutomu Kouno
CSChikako Shimizu
Chikako Shimizu
YFYasuhiro Fujiwara
Yasuhiro Fujiwara

23 March 2012 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYuki Kojima
Yuki Kojima
KHKenji Hashimoto
Kenji Hashimoto
MAMasashi Ando
Masashi Ando
KYKan Yonemori
Kan Yonemori
AHAkihiro Hirakawa
Akihiro Hirakawa
YFYasuhiro Fujiwara
Yasuhiro Fujiwara